Fondazione Italiana Linfomi - Ets

This phase 3 trial compares a shorter chemotherapy regimen (4 cycles) against the standard 6 cycles, both combined with immunotherapy, for people with newly diagnosed, high-tumor-burden follicular lymphoma. The goal is to see if the shorter treatment is just as effective at keepi…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (R-CHOP) helps people with a hard-to-treat type of lymphoma called ABC-DLBCL. About 75 adults aged 18-65 with a poor prognosis will receive the combo for 6 cycles, then take ibrutinib alone for 1…

This study follows about 212 people in Italy with Waldenström's macroglobulinemia, a rare blood cancer, who are taking the drug zanubrutinib. Researchers are tracking how long patients stay on the drug, side effects, and overall treatment outcomes. The goal is to understand how w…

This phase 3 trial tests whether adding lenalidomide to rituximab maintenance therapy works better than rituximab alone for people with relapsed follicular lymphoma who cannot have a stem cell transplant. About 128 participants will receive either the combination or rituximab alo…

This study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study examines stored tissue samples from 160 adults with mantle cell lymphoma whose cancer returned or didn't respond after initial chemotherapy and rituximab. Researchers will analyze the samples to identify genetic and cellular features linked to treatment resistance. The…

This study reviews medical records of 241 adults who developed a rare cancer called PTLD after an organ or stem cell transplant. Researchers aim to understand patient survival, disease features, and current treatments. No new treatments are tested; the goal is to gather informati…